VERACYTE, INC. VCYT
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
7/9
Piotroski F — financial health
15.66
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $517.1M | $66.4M | $362.5M | $126.6M | $1.3B |
| 2024 | $445.8M | $24.1M | $298.1M | $63.8M | $1.2B |
| 2023 | $361.1M | -$74.4M | $229.7M | $34.3M | $1.0B |
| 2022 | $296.5M | -$36.6M | $175.7M | -$1.0M | $1.1B |
| 2021 | $219.5M | -$75.6M | — | -$37.0M | $1.1B |
| 2020 | $117.5M | -$34.9M | — | -$12.5M | $421.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| EASTHAM KARIN | director | 2026-06-18 | Sell | 3,200 | $52.78 |
| EASTHAM KARIN | director | 2026-06-18 | Sell | 529 | $53.55 |
| JONES EVAN/ FA | director | 2026-06-11 | Grant | 5,272 | — |
| Shafer David Brent | director | 2026-06-11 | Grant | 5,272 | — |
| Barr Eliav | director | 2026-06-11 | Grant | 5,272 | — |
| Holstein Jens | director | 2026-06-11 | Grant | 5,272 | — |
| Bhanji Muna | director | 2026-06-11 | Grant | 5,272 | — |
| Miller Thomas F. | director | 2026-06-11 | Grant | 5,272 | — |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 15.66 (safe)
- Working capital / assets 0.305
- Retained earnings / assets -0.269
- EBIT / assets 0.041
- Equity / liabilities 13.579
Source: SEC EDGAR filings · CIK 0001384101 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.